Table 1. Demographic and baseline characteristics of the patients per group (N = 76).a .
| Characteristic | Group | p | |
|---|---|---|---|
| RATS | VATS | ||
| (n = 37) | (n = 39) | ||
| Age, years | 68.4 (65.2-71.5) | 65.7 (61.8-69.5) | 0.31 |
| Female | 20 (54.0%) | 22 (56.4%) | 1.00 |
| BMI, kg/m2 | 27.5 (26.2-28.8) | 26.5 (24.9-28.1) | 0.24 |
| FEV1, L | 2.2 (2.0-2.4) | 2.1 (1.9-2.3) | 0.33 |
| FEV1, % of predicted | 87.3 (81.8-92.8) | 81.5 (77.5-85.5) | 0.19 |
| Never smoker | 12 | 11 | 0.78 |
| COPD | 12 | 18 | 0.28 |
| Morbid obesity (BMI >34.9 kg/m2) | 3 | 3 | 1.00 |
| Hypertension | 24 | 21 | 0.35 |
| Diabetes mellitus | 7 | 11 | 0.42 |
| Cardiac disease | 5 | 3 | 0.47 |
| Liver disease | 2 | 5 | 0.43 |
| Kidney disease | 2 | 1 | 0.61 |
| NSCLC | 34b | 35c | 1.00 |
| Tumor size, cm | 2.32 (1.90-2.74) | 2.45 (2.11-2.79) | 0.65 |
RATS: robotic-assisted thoracic surgery; VATS: video-assisted thoracic surgery; and NSCLC: non-small cell lung cancer. aValues expressed as n or median (95% CI), except where otherwise indicated. bMetastatic breast cancer, in 1; inflammatory myofibroblastic tumor, in 1; and atypical adenomatous hyperplasia, in 1. cMetastatic melanoma, in 1; metastatic renal cell carcinoma, in 2; and small cell lung cancer, in 1.